arthritis rheumatoid

Rheumatoid arthritis affects roughly 1% of the global population and remains a leading cause of disability and cardiovascular comorbidity. The advent of biologic and targeted synthetic DMARDs has transformed disease outcomes, with remission now an achievable target for many patients. Current research focuses on personalised treatment selection, subclinical cardiovascular risk, and the growing armamentarium of JAK inhibitors.